Sangamo Therapeutics, Inc.
SGMO
$0.4831
-$0.0169-3.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 63.76M | 57.80M | 52.29M | 12.28M | 18.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 63.76M | 57.80M | 52.29M | 12.28M | 18.76M |
| Cost of Revenue | 102.23M | 112.12M | 139.35M | 168.71M | 203.13M |
| Gross Profit | -38.48M | -54.32M | -87.06M | -156.43M | -184.38M |
| SG&A Expenses | 43.22M | 44.93M | 48.36M | 53.63M | 53.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 145.45M | 157.05M | 187.71M | 222.34M | 256.83M |
| Operating Income | -81.70M | -99.25M | -135.42M | -210.06M | -238.07M |
| Income Before Tax | -79.60M | -98.11M | -134.85M | -248.51M | -333.22M |
| Income Tax Expenses | -146.00K | -167.00K | -12.00K | 1.17M | -5.17M |
| Earnings from Continuing Operations | -79.45 | -97.94 | -134.84 | -249.68 | -328.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -79.45M | -97.94M | -134.84M | -249.68M | -328.05M |
| EBIT | -81.70M | -99.25M | -135.42M | -210.06M | -238.07M |
| EBITDA | -76.98M | -94.14M | -129.73M | -200.09M | -225.09M |
| EPS Basic | -0.38 | -0.51 | -0.74 | -1.37 | -1.86 |
| Normalized Basic EPS | -0.24 | -0.30 | -0.45 | -0.69 | -0.80 |
| EPS Diluted | -0.39 | -0.52 | -0.74 | -1.37 | -1.86 |
| Normalized Diluted EPS | -0.24 | -0.31 | -0.45 | -0.69 | -0.80 |
| Average Basic Shares Outstanding | 842.75M | 802.82M | 770.25M | 739.08M | 709.46M |
| Average Diluted Shares Outstanding | 848.73M | 808.80M | 776.23M | 739.08M | 709.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |